Clinical Research of Recombinant Human Brain Natriuretic Peptide in the Treatment of Refractory Heart Failure
LIN Dong-qun
LI Dan-chai
Abstract：Objective:To investigate the clinical efficacy and safety of Recombinant Human Brain Natriuretic Peptide in the treatment of refractory heart failure.Method:130 patients with refractory heart failure were randomly divided into Recombinant Human Brain Natriuretic Peptide treatment group(the observation group) and Nitroglycerin treatment group(the control group).Both groups were provided equally basic treatment,to observe two groups of patients’ cardiac function improved and the occurrence of adverse reactions.Result:Upon treatment,left ventricular diastolic diameter(LVEDD) of the observation group was smaller than the control group,and left ventricular ejection fraction(LVEF) was higher than that of the control group(P<0.05).The total treatment effective rate of the observation group was 92.30%,was higher than 67.69%of the control group(P<0.05).The hypokalemia,cardiac arrhythmias,nausea and other side-effect reactions of the observation group compared with the control group,there was not statistically significant(P>0.05).Conclusion:The treatment of Recombinant Human Brain Natriuretic Peptide on patients with refractory heart failure is with safety and therapeutic effect is superior to Nitroglycerin.
Keywords：Refractory heart failureRecombinant Human Brain Natriuretic PeptideHeart failure
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 26-26,27 )